Arkolith/Insider Trading/RLAY/Form 4

Catinazzo Thomas

Chief Financial OfficerRelay Therapeutics, Inc. (RLAY) · full profile →Form 4 · filed Jun 24, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.2M
Net Open-Market Flow
-$3.2M
Transactions
10
7 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 22, 2026Sell(S)18K$17.01$301K177K
Jun 22, 2026Option exercise(M)56K$5.04$284K234K
Jun 22, 2026Sell(S)56K$16.97$956K177K
Jun 22, 2026Option exercise(M)62K$5.22$321K239K
Jun 22, 2026Sell(S)62K$16.97$1.0M177K
Jun 22, 2026Option exercise(M)52K$4.45$229K229K
Jun 22, 2026Sell(S)52K$16.97$875K177K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 22, 2026Option exercise(M)56K—$00
Jun 22, 2026Option exercise(M)62K—$00
Jun 22, 2026Option exercise(M)52K—$0223K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-281061) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML